Skip to content
  • Fraser M. Cracking the Code: Prostate Cancer, Genomics, and You. Prostate Cancer Support Canada Coast to Coast Meeting. August 31, 2021.
  • Fraser M. Liquid Biopsy for Diagnostic and Prognostic Biomarker Discovery in Localized Prostate Cancer. 2020 ISBER Virtual Symposium. October 22, 2020.
  • Fraser M. The Many Genomes of Prostate Cancer. Genomics Live 2019. Basel, Switzerland. Dec 5, 2019.
  • Fraser M. Clinico-Genomics of Localized Prostate Cancer: Moving Beyond the Bench. 11th Annual Princess Margaret Cancer Centre Uro-Oncology Dialogue. Niagara-on-the-Lake, ON. September 7, 2019.
  • Fraser M. The Clinico-Genomics of Localized, Non-Indolent Prostate Cancer. Department of Urology, University of Michigan, Ann Arbor, MI, December 17, 2018.
  • Fraser M. The Clinico-Genomics of Localized, Non-Indolent Prostate Cancer. 10th Annual Next Generation Sequencing Congress UK, London, UK. November 8, 2018. * – keynote speaker
  • Fraser M. Translational Genomics for Prostate Cancer. GU Research Rounds, Princess Margaret Cancer Centre, Toronto, ON, September 24, 2018.
  • Fraser M. The Clinico-Genomics of Localized, Non-Indolent Prostate Cancer. Lerner Research Institute, Cleveland Clinic, Cleveland, OH, August 16, 2018.
  • Fraser M. The Past, Present, and Future of Genomic Biomarkers for Localized, Non-Indolent Prostate Cancer. NextGen Star Major Symposium Keynote Lecture, American Association for Cancer Research Annual Meeting, Chicago, IL, April 2018.
  • Fraser M. Multi-Omic Approaches to Identify Aggressive Localized Prostate Cancer. University of Toronto, Department of Urology Cancer Genomics Workshop, November 28, 2017.
  • Fraser M. Defining Novel Clinical Relevant Subtypes of Curable Prostate Cancer Using Next-Generation Sequencing. Next Generation Sequencing Congress USA. Boston, MA, October 4, 2016. * – keynote speaker
  • Fraser M. Biology and Biomarkers in Curable Prostate Cancer: The CPC-GENE Experience. Urologic Oncology Fellows Seminar.  Toronto, ON, May 3, 2016.
  • Fraser M. Defining The Mutational Landscape of Localized, Potentially Curable Prostate Cancer. Ottawa Health Research Institute Seminar Series. Ottawa, ON, May 4, 2015.
  • Fraser M. The Canadian Prostate Cancer Genome Network (CPC-GENE) Program. Urologic Oncology Fellows Seminar.  Toronto, ON, May 5, 2015.
  • Fraser M. Developing Prognostic Biomarkers for Localized Prostate Cancer Using Whole-Genome Sequencing. Next Generation Sequencing Congress USA. Boston, MA, October 28, 2015.
  • Fraser M. CPC-GENE: A National Outcomes-Based Sequencing Initiative. Princess Margaret Cancer Centre Prostate Research Rounds. Toronto, Oct 29, 2014.
  • Fraser M. The Canadian Prostate Cancer Genome Network (CPC-GENE): Defining Genomic and Clinical Heterogeneity In Localized, Potentially Curable Prostate Cancer. 6th Annual Next Generation Sequencing Congress, London, UK. Nov 21, 2014.
  • Fraser M. The Canadian Prostate Cancer Genome Network: Milestones and Progress. International Cancer Genome Consortium (ICGC) Pan-Prostate Sequencing Initiative Meeting, London, UK. Oct 3, 2014.
  • Fraser M. Novel Mechanisms of AKT Phosphorylation in Response to DNA Double Strand Breaks.  Institute of Zoology, Chinese Academy of Sciences.  Beijing, China, July 13, 2011.
  • Fraser M. A subset of nuclear Akt is phosphorylated on Ser473 in an ATM-dependent manner in response to radiation-induced DNA double strand breaks.  11th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology.  Ermatingen, Switzerland, June 27-29, 2009.
  • Fraser M. (2007) Cancer: A Disease of the Genome. John Fraser Secondary School, Mississauga, ON.
  • Fraser M. (2006) The NCIC Prevention Initiative. National Cancer Institute of Canada/Canadian Cancer Society
  • Fraser M. (2006) Role and regulation of p53-mediated apoptosis: possible implications for chemoresistance in human ovarian cancer cells.  University of Ottawa, Department of Cellular and Molecular Medicine, Research Seminar.
  • Fraser M. and Tsang B.K. Regulation of p53-Mediated Apoptosis in Human Ovarian Cancer Cells. 2005 Ottawa Reproductive Biology Workshop, Ottawa, ON.
  • Fraser M., Leung B., Yan X., Cheng J.Q., and Tsang B.K. p53 Status is a Determinant of Xiap-/Akt-Mediated Chemoresistance in Human Ovarian Cancer. 2003 Ottawa Health Research Institute Research Day, Ottawa, ON.
  • Fraser M., Leung B., Yan X., Cheng J.Q., and Tsang B.K. (2003) p53 Status is a Determinant of Akt-Mediated Chemoresistance in Human Ovarian Cancer. 2003 Ottawa Reproductive Biology Workshop, Ottawa, ON.
  • Fraser M., and Tsang B.K. (2001) Xiap and Chemoresistance in Human Ovarian Cancer. 1st Annual Ottawa Health Research Day Retreat, Ottawa, ON.